Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Treasury Shares (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Treasury Shares for 16 consecutive years, with $17.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 11.66% to $17.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.4 million, a 11.66% increase, with the full-year FY2025 number at $17.4 million, up 11.66% from a year prior.
  • Treasury Shares was $1.6 million for Q4 2025 at Lemaitre Vascular, up from $1.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.6 million in Q4 2025 to a low of $55.0 in Q3 2022.
  • A 5-year average of $958659.5 and a median of $1.6 million in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: rose 4.84% in 2022, then increased 13.76% in 2025.
  • Lemaitre Vascular's Treasury Shares stood at $12.4 million in 2021, then rose by 5.18% to $13.0 million in 2022, then rose by 6.54% to $13.9 million in 2023, then increased by 12.37% to $15.6 million in 2024, then increased by 11.66% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Treasury Shares are $17.4 million (Q4 2025), $16.2 million (Q3 2025), and $16.2 million (Q2 2025).